VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RCEL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RCELAvita Medical Inc.
$15.77$392M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. RCEL
  4. Financial Ratios

Avita Medical Inc. (RCEL) Financial Ratios

Latest Ratios: P/E Ratio -13.5x · EV/EBITDA N/A · ROE N/A. (1996–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

RCEL Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$392M$96M$331M$348M$165M$292M$416M$620M$691M$50M$41M
Enterprise Value$428M$132M$363M$368M$148M$238M$307M$548M$671M$30M$36M
P/E Ratio →-13.48——————————
P/S Ratio4.631.345.166.934.798.8414.2443.4588.2829.2726.72
P/B Ratio——73.647.081.952.793.608.5633.181.946.16
P/FCF———————————
P/OCF———————————

P/E links to full P/E history page with 30-year chart

RCEL EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue—1.845.657.344.297.2010.4938.4285.7017.5823.51
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———————————

RCEL Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin82.1%82.1%85.8%84.5%82.4%81.5%79.6%79.2%76.8%41.2%57.2%
Operating Margin-59.4%-59.4%-88.1%-85.1%-79.9%-76.1%-90.8%-299.2%-466.4%-812.0%-1073.2%
Net Profit Margin-67.8%-67.8%-96.3%-70.6%-77.5%-76.1%-90.9%-294.7%-458.6%-1370.8%-975.0%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE——-231.0%-52.9%-28.2%-22.8%-28.3%-90.2%-154.0%-143.9%-222.0%
ROA-71.4%-71.4%-64.6%-33.7%-24.9%-20.8%-25.6%-77.7%-125.9%-113.3%-161.5%
ROIC-114.8%-114.8%-80.3%-46.8%-34.9%-66.6%-615.7%-4788.2%-841.9%-273.7%-561.6%
ROCE-159.7%-159.7%-71.6%-45.9%-28.3%-22.3%-27.5%-88.9%-150.1%-79.6%-231.2%

RCEL Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity——10.220.860.010.020.010.03—0.01—
Debt / EBITDA———————————
Net Debt / Equity——7.100.41-0.20-0.51-0.95-0.99-0.97-0.77-0.74
Net Debt / EBITDA———————————
Debt / FCF———————————
Interest Coverage-8.71-8.71-10.53-29.90-1663.31-864.69-1205.59—-933.20——

RCEL Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio0.570.572.837.888.1810.0716.4210.175.387.753.72
Quick Ratio0.460.462.477.467.989.8416.2010.025.227.353.19
Cash Ratio0.290.291.786.757.429.3114.999.554.505.161.94
Asset Turnover—1.270.810.450.350.280.230.170.300.050.15
Inventory Turnover1.851.851.251.392.842.863.612.642.450.640.49
Days Sales Outstanding—46.4267.9657.6652.6037.8798.4364.16118.2769.7452.60

RCEL Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield———————————
FCF Yield———————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$28M$26M$25M$25M$24M$20M$20M$22M$9M$7M

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetStrained
Cash FlowImproving
Top Statement Risk

Negative equity against collapsing liquidity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Sales Multiple Carries Loss-Making Profile

Because trailing earnings are negative, RCEL's -8.72X P/E is uninterpretable, leaving the 5.27X price-to-sales ratio as the operative multiple; per market data compiled for the medical device peer set, that sales multiple prices Avita far above the near-0.8X book value attaching to XTNT.

A 5.27X sales multiple is difficult to justify against a business generating roughly -35% net margins, and with EV/EBITDA and forward P/E both unavailable, investors are effectively pricing optionality on future commercialization rather than present earning power. The absence of a usable earnings or EBITDA anchor means the discount to any profitability benchmark is unknowable today, so the sales multiple should be stress-tested against the cash burn implied by the negative FCF margin of -16.6%.

Gross Margin Erodes as Overhead Falls Short

Operating margin improved to -31.6% in 2026Q2 from -155.0% in 2024Q1, yet net margin of -35.3% still implies losses on every dollar sold; according to recent SEC filings, gross margin slipped to 81.9% from 87.6% two years earlier, a 570bp fade operating leverage cannot offset.

The narrowing operating loss reflects overhead reduction more than pricing power, since gross margin has fallen in roughly five of the ten quarters observed while revenue recovered, suggesting the unit economics themselves are weakening rather than merely being scaled. The consistently negative gap between operating and net margin, wider than three points in several quarters, points to material non-operating items that make adjusted or headline profitability readings unreliable as a measure of true earning power.

ROIC Deepens Negative Despite Revenue Recovery

ROIC of -36.5% in 2026Q2 remains far below the -19.7% reading of 2024Q4, indicating that capital deployed into the platform appears to be destroying rather than compounding value; as reported in Avita's financial statements, asset turnover of 0.44 cannot rescue returns while operating margins stay negative.

The deterioration in ROIC alongside rising asset turnover implies the driver is margin, not efficiency: the company is moving assets faster but converting them into deeper losses per unit of capital employed. With equity already negative, ROE is uninformative and effectively undefined, so ROIC against invested capital is the only defensible return measure — and its persistent sub--30% territory suggests no path to a positive cost-of-capital spread on current operations.

Payables Stretch Compresses Cash Cycle

The cash conversion cycle collapsed from 206 days in 2024Q1 to 16 days in 2026Q2, driven by DIO falling to 132 days from 384 and DSO to 41 from 71, while DPO of 158 days still exceeds receivable collection by nearly four times, per Avita's quarterly disclosures.

A 16-day cycle could superficially read as best-in-class working capital management, but the composition suggests supplier financing and inventory drawdown are subsidizing operations rather than structural process gains, a pattern that warrants investigation into whether payables terms are sustainable. The simultaneous fall in DIO and DPO from their 2024–2025 peaks may indicate inventory is being liquidated to fund the burn, which would flatter the cycle while eroding the manufacturing base underpinning gross margin.

Liquidity Buffer Inverts Into Deficit

The current ratio fell from 7.25 in 2024Q1 to 0.41 in 2026Q2 with the quick ratio at 0.34, meaning circulating assets cover barely two-fifths of short-term obligations; according to Avita's reported balance sheets, this sits alongside $9.1M of cash against $75.6M of total liabilities.

The relatively small spread between current and quick ratios implies inventory is not the dominant current asset cushion, so even liquidating remaining inventory would not restore coverage — a materially worse stress profile than the headline current ratio alone suggests. Under severe stress, coverage would hinge on the ability to roll or restructure obligations, and with interest coverage of -4.22X confirming earnings cannot service debt, investors should monitor whether liquidity is being managed through payable extension rather than genuine asset recovery.

P/E Misapplied to Pre-Profit Device Makers

The ratio most commonly misread for this business model is the P/E, whose -8.72X reading measures loss magnitude rather than cheapness or richness; as peer market data shows XTNT at 9.17X earnings, any RCEL earnings multiple would mechanically swing toward zero as losses narrow, per compiled comparisons.

For a commercial-stage device company still funding SG&A above revenue, the P/E obscures the real questions of cash runway, gross margin trajectory, and the revenue scale required to reach breakeven, none of which the multiple captures. EV/EBITDA is nearly as misleading while EBITDA remains negative, so sales-based measures adjusted for burn — such as EV/Sales net of quarterly free cash outflow — would better frame what the market is actually paying for.

Download Financial Ratios Data

Includes 30+ ratios · 30 years · Updated daily

Consensus & Technical Research Suite
Open RCEL Terminal

RCEL Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

RCEL — Frequently Asked Questions

Quick answers to the most common questions about buying RCEL stock.

What is Avita Medical Inc.'s P/E ratio?

Avita Medical Inc.'s current P/E ratio is -13.5x. This places it at the 50th percentile of its historical range.

Is RCEL stock overvalued?

Based on historical data, Avita Medical Inc. is trading at a P/E of -13.5x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are Avita Medical Inc.'s profit margins?

Avita Medical Inc. has 82.1% gross margin and -59.4% operating margin.